In an interview conducted during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes, Uwe Platzbecker, MD, Director of the Medical Clinic I at the University of Leipzig, in Leipzig, Germany, discusses management considerations for cytopenia in patients with MDS. Dr Platzbecker presents results from a Phase 2/3 trial designed to investigate imetelstat in patients with low- and intermediate-risk MDS. He also discusses anti-inflammatory treatments that are in early development.